Compare · CLXT vs UAN
CLXT vs UAN
Side-by-side comparison of Calyxt Inc. (CLXT) and CVR Partners LP (UAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CLXT and UAN operate in Agricultural Chemicals (Industrials), so they compete in similar markets.
- UAN is the larger of the two at $1.25B, about 20.2x CLXT ($62.0M).
- CLXT has more recent analyst coverage (2 ratings vs 0 for UAN).
- Company
- Calyxt Inc.
- CVR Partners LP
- Price
- $31.50+428.97%
- $117.65-1.10%
- Market cap
- $62.0M
- $1.25B
- 1M return
- -
- -7.73%
- 1Y return
- -
- +43.11%
- Industry
- Agricultural Chemicals
- Agricultural Chemicals
- Exchange
- NASDAQ
- NYSE
- IPO
- 2017
- 2011
- News (4w)
- 0
- 0
- Recent ratings
- 2
- 0
Calyxt Inc.
Calyxt, Inc., a technology company, focuses on delivering plant-based solutions in the United States. It engages in the development of improved digestibility alfalfa; high fiber wheat; high oleic low linolenic soybeans; winter oats; hemp; fat soybeans; and cold storable potatoes. As of March 4, 2021, the company had nine projects at Phase I stage or later in development across alfalfa, hemp, oats, soybeans, and wheat. Calyxt, Inc. has a research collaboration with NRGene, which includes the adoption of NRGene's cloud-based genomics platform to support various research projects; and a commercialization agreement with S&W Seed Company for the exclusive license of an improved quality alfalfa seed in the United States and various geographies outside the United States. The company was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015. Calyxt, Inc. was incorporated in 2010 and is headquartered in Roseville, Minnesota. Calyxt, Inc. is a subsidiary of Cellectis S.A.
CVR Partners LP
CVR Partners, LP, together with its subsidiaries, produces and distributes nitrogen fertilizer products in the United States. The company offers ammonia products for agricultural and industrial customers; and urea and ammonium nitrate products to agricultural customers, as well as retailers and distributors. CVR GP, LLC serves as the general partner of the company. CVR Partners, LP was founded in 2007 and is based in Sugar Land, Texas.
Latest CLXT
- Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
- SEC Form SC 13G/A filed by Calyxt Inc. (Amendment)
- Calyxt Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Riggs Rory B converted options into 1,500,000 shares and acquired 1,505,967 units of Class B Common Stock, increasing direct ownership by 128% to 3,103,788 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.
- Calyxt Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Riggs Rory B disposed of 39,476 shares and bought $5,470,992 worth of shares (517,107 units at $10.58), increasing direct ownership by 47% to 1,622,495 units (SEC Form 4)
- Calyxt Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Calyxt Inc.
Latest UAN
- SEC Form 10-Q filed by CVR Partners LP
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- CVR Partners Reports First Quarter 2026 Results
- CVR Partners to Release First Quarter 2026 Earnings Results
- SEC Form 3 filed by new insider Turbidy Trevor
- CVR Partners LP filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- CVR Partners LP filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- CVR Partners Files Form 10-K Annual Report For Fiscal Year Ended December 31, 2025
- SEC Form 10-K filed by CVR Partners LP
- CVR Partners LP filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits